Citigroup’s Day One Biopharmaceuticals DAWN Stock Holding History

Citigroup’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-115,000	Closed	-$2.47M	–	5839
2026 Q1	$2.47M	Buy	115,000 +15,000	+15%	+$211K	﹤0.01%	2533
2025 Q4	$932K	Buy	+100,000	New	+$835K	﹤0.01%	3185
2025 Q3	–	Sell	-62,000	Closed	-$403K	–	6135
2025 Q2	$403K	Hold	62,000	–	–	﹤0.01%	3748
2025 Q1	$492K	Sell	62,000 -24,900	-29%	-$268K	﹤0.01%	3692
2024 Q4	$1.1M	Buy	86,900 +27,000	+45%	+$376K	﹤0.01%	3292
2024 Q3	$834K	Buy	59,900 +29,900	+100%	+$427K	﹤0.01%	3404
2024 Q2	$413K	Buy	+30,000	New	+$439K	﹤0.01%	3511

Other funds holding DAWN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Citigroup's DAWN Position: Q2 2026 in Review

Citigroup sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 13,848 shares — an estimated $297K sold.

Citigroup first reported a position in DAWN in Q3 2021 and held it in 19 quarters. The position peaked at $2.83M in Q1 2024. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.

Citigroup reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
Citigroup sold 13,848 Day One Biopharmaceuticals shares in Q2 2026, an estimated $297K.
Citigroup first reported a position in Day One Biopharmaceuticals in Q3 2021 and held it in 19 quarters.
Citigroup's Day One Biopharmaceuticals position peaked at $2.83M in Q1 2024.
1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.